![\"\"](\"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/01\/image001.png\")
<\/h3>\nThe management of low-density lipoprotein cholesterol (LDL-C) has transitioned into an intensive paradigm emphasizing sustained lowering, often summarized as \u201clower for longer.\u201dCentral to this shift is the therapeutic targeting of proprotein convertase subtilisin\/kexin type 9(PCSK9). While cardiovascular benefits are well-established, concerns regarding neurocognitive safety at extremely low LDL-C levels have persisted. This review synthesizes genetic,mechanistic, and clinical evidence addressing the relationship between PCSK9 modulation,lifelong lipid exposure, and neurodegenerative risk, specifically Alzheimer\u2019s disease (AD).<\/p>\n
<\/h3>\nThe discovery of PCSK9 as a key regulator of LDL receptor (LDLR) density has revolutionized lipidology [1-3]. Monoclonal antibodies and gene-editing techniques targeting PCSK9 allow for LDL-C reductions exceeding 60%, often reaching levels below 20 mg\/dL [15]. Given the high cholesterol content of the brain, the safety of such profound systemic depletion remains acritical area of longitudinal analysis.<\/p>\n
PCSK9 is a serine protease that binds to the epidermal growth factor-like repeat A (EGF-A) domain of the hepatic LDLR [2]. Under physiological conditions, this binding targets the receptor for lysosomal degradation, preventing its recycling to the cell surface and thereby increasing circulating LDL-C. Pharmacological inhibition\u2014via monoclonal antibodies or newer strategies like CRISPR-based base editing\u2014interrupts this interaction, restoring LDLR availability and enhancing LDL clearance from the plasma [3, 18].<\/p>\n
Human genetics provide a \u201cnatural experiment\u201d to assess long-term PCSK9 modulation. Loss-of-function (LoF) variants, such as the R46L variant common in European populations, lead to lifelong lower LDL-C and significant protection against atherosclerotic cardiovascular disease(ASCVD) [4-5]. Importantly, rare individuals with homozygous \u201cnull\u201d phenotypes exhibit LDL-Clevels as low as 15 mg\/dL without overt neurocognitive impairment, suggesting that systemicLDL-C depletion is compatible with normal human physiology [6].<\/p>\n
A critical mechanistic safeguard for neurocognitive health is the isolation of brain cholesterol metabolism. Approximately 25% of the body\u2019s cholesterol is located in the CNS, yet it is functionally separated from systemic pools by the blood\u2013brain barrier (BBB) [10]. Brain cholesterol is synthesized de novo primarily by astrocytes and neurons; it does not depend on circulating LDL-C particles [10]. Furthermore, monoclonal antibodies targeting PCSK9 are largemolecules that do not cross an intact BBB, precluding direct CNS interaction [1].<\/p>\n
Early Mendelian Randomization (MR) studies raised speculative concerns regarding a possible increase in AD risk associated with lower LDL-C [9]. However, subsequent large-scale MR analyses involving over 115,000 individuals and higher-powered meta-analyses effectively refute these signals [9, 17]. Specifically, studies targeting LDL-C-lowering variants in the PCSK9 and HMGCR loci show a neutral odds ratio (OR \u2248 0.97) for AD, and some data suggest potential protective effects when non-HDL cholesterol is lowered over a lifetime [16-17].<\/p>\n
Randomized controlled trials (RCTs) provide the most direct evidence of safety. The EBBINGHAUS study, a prospective neurocognitive substudy of the FOURIER trial, utilized objective cognitive testing in nearly 2,000 patients [11]. Over a median follow-up of 19 months,no differences were observed between evolocumab and placebo. Long-term extension data(FOURIER-OLE) reached follow-up durations of 7+ years, demonstrating sustained cognitivestability even among those achieving LDL-C levels < 20 mg\/dL [12, 15]. Similar safety profileshave been established for alirocumab in the ODYSSEY OUTCOMES trial and subsequent meta-analyses [13].<\/p>\n
The log-linear relationship between LDL-C reduction and ASCVD risk reduction remains consistent across the therapeutic spectrum [14]. Clinical evidence suggests that the benefit of aggressive lowering continues without a plateau, while safety markers for dementia and cognitive decline remain flat [15].<\/p>\n
Comprehensive analysis of genetic epidemiology, mechanistic biology, and randomized clinical trials consistently supports the conclusion that PCSK9 inhibition and extremely low LDL-C do not increase the risk of Alzheimer\u2019s disease or other dementias. Local regulation of CNS cholesterol synthesis and BBB isolation provide a biological basis for systemic lipid management without neurocognitive consequence.<\/p>\n
References<\/strong><\/p>\n Kan LDL te laag zijn? Wat PCSK9-remmers betekenen voor de hersengezondheid<\/p>\n PCSK9-remmers behoren tot de krachtigste cholesterolverlagende behandelingen die er zijn. Ze kunnen het LDL-gehalte (\u201cslecht cholesterol\u201d) met 50\u201360% of meer verlagen \u2014 en in sommige gevallen zelfs tot onder de 20 mg\/dL brengen.<\/p>\n Dat is een ongelooflijk hulpmiddel om hartinfarcten en beroertes te voorkomen. Maar het roept ook een terechte vraag op: Als de hersenen cholesterol nodig hebben, zou LDL dan \u201cte laag\u201d kunnen worden en het risico op de ziekte van Alzheimer of dementie kunnen verhogen?<\/p>","protected":false},"author":16,"featured_media":8586,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[227,219,223,224],"tags":[],"class_list":["post-8531","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-apob-and-lipid-science","category-lipids-medications-and-testing","category-plaque-arteries-and-disease","category-regression-and-reversal"],"acf":[],"yoast_head":"\n\n